A detailed history of Franklin Resources Inc transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Franklin Resources Inc holds 181,582 shares of KRYS stock, worth $32 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
181,582
Previous 131,465 38.12%
Holding current value
$32 Million
Previous $23.4 Million 42.55%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$153.12 - $183.64 $7.67 Million - $9.2 Million
50,117 Added 38.12%
181,582 $33.3 Million
Q1 2024

May 13, 2024

BUY
$108.01 - $179.35 $11.3 Million - $18.8 Million
104,919 Added 395.23%
131,465 $23.4 Million
Q4 2023

Feb 09, 2024

BUY
$96.0 - $128.29 $6,528 - $8,723
68 Added 0.26%
26,546 $3.29 Million
Q3 2023

Nov 13, 2023

BUY
$108.51 - $130.22 $1.22 Million - $1.46 Million
11,238 Added 73.74%
26,478 $3.07 Million
Q2 2023

Aug 11, 2023

BUY
$78.48 - $130.32 $832,515 - $1.38 Million
10,608 Added 229.02%
15,240 $1.79 Million
Q4 2022

Feb 10, 2023

BUY
$63.14 - $79.9 $1,578 - $1,997
25 Added 0.54%
4,632 $366,000
Q3 2022

Nov 14, 2022

BUY
$64.85 - $82.4 $73,993 - $94,018
1,141 Added 32.92%
4,607 $321,000
Q2 2022

Aug 11, 2022

SELL
$48.93 - $73.47 $13,260 - $19,910
-271 Reduced 7.25%
3,466 $228,000
Q1 2022

May 13, 2022

BUY
$51.99 - $72.11 $194,286 - $269,475
3,737 New
3,737 $249,000
Q4 2021

Feb 11, 2022

SELL
$39.81 - $88.24 $5.57 Million - $12.4 Million
-140,004 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$62.14 - $81.82 $932,100 - $1.23 Million
15,000 Added 12.0%
140,004 $9.52 Million
Q1 2021

May 13, 2021

BUY
$59.42 - $85.46 $7.43 Million - $10.7 Million
125,004 New
125,004 $9.63 Million

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.53B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Franklin Resources Inc Portfolio

Follow Franklin Resources Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

News

Stay updated on Franklin Resources Inc with notifications on news.